Gastric Cancer (GC)NCT07332104
The Application of Extracellular Vesicle Detection in Gastric Juice Based on Metamaterial Sensing in the Diagnosis of Gastric Cancer and Related Diseases
An observational study of Gastric Cancer (GC) and Gastric Cancer (Diagnosis), run by Beijing Friendship Hospital.
Trial summary
After obtaining informed consent from the patients, all the medical history and treatment records of the patients who underwent gastroscopy since the onset of the disease, as well as gastric fluid samples, including laboratory and imaging data, were collected and recorded. Read more about this study
- Who is it for?
- Ages 40 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Gastric Cancer (GC), Gastric Cancer (Diagnosis)
- What is being tested?
- In vitro surface plasmon resonance detection
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 15 Dec 2025to 15 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Gastric cancer and non-cancer patients
Who may be able to join
- Patients underwent gastroscopy and treatment at the Endoscopy Center of Beijing Friendship Hospital, Capital Medical University, and received pathological biopsy.
- Previous gastroscopy suggested the possibility of lesions.
- No previous history of gastrointestinal cancer.
Who cannot join
- Patients could not cooperate with the examination or had contraindications to endoscopy.
- Previous history of gastrointestinal tumors, gastrointestinal surgery, physical and chemical injuries of the gastrointestinal tract.
- Severe bile reflux.
- Take simethicone and other defoaming agents before examination.
- Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
After obtaining informed consent from the patients, all the medical history and treatment records of the patients who underwent gastroscopy since the onset of the disease, as well as gastric fluid samples, including laboratory and imaging data, were collected and recorded. The medical history and treatment records and gastric fluid samples were analyzed.
- Conditions
- Gastric Cancer (GC), Gastric Cancer (Diagnosis)
- Being tested
- In vitro surface plasmon resonance detection
- Keywords
- Gastric cancer, Extracellular vesicles
- Medical subject headings
- Stomach Neoplasms, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
In vitro surface plasmon resonance detectionDiagnostic test
Gastric juice from patients was removed for isolation of extracellular vesicles and surface plasmon resonance detection in vitro
| Study group | Role | What they receive |
|---|---|---|
| gastric cancer | Patients diagnosed with gastric cancer Receives: Diagnostic Test: In vitro surface plasmon resonance detection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Surface plasmon resonance(SPR) detection of extracellular vesicles in gastric juice of patients with gastric cancer has large shift and spectral changes
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start15 Dec 2025 (estimated)
- Primary completion15 Dec 2026 (estimated)
- Study completion15 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric Cancer (GC)Studies of the same condition, open and under way.
- More trials run by Beijing Friendship HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Friendship Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Min Li, Beijing Friendship Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07332104
- Sponsor's protocol ID
- BFHZS20240020
- Other IDs
- No. BFHZS20240020
- Status last verified
- Dec 2025
- First submitted
- 14 Dec 2025
- Last updated
- 12 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Application of Extracellular Vesicle Detection in Gastric Juice Based on Metamaterial Sensing in the Diagnosis of Gastric Cancer and Related Diseases
- ClinicalTrials.gov ID
- NCT07332104
- Acronym / sponsor ID
- BFHZS20240020
- Conditions
- Gastric Cancer (GC), Gastric Cancer (Diagnosis)
- Keywords
- Gastric cancer, Extracellular vesicles
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Beijing Friendship HospitalUniversity, hospital or other
- Study start
- 15 Dec 2025 (estimated)
- Primary completion
- 15 Dec 2026 (estimated)
- Study completion
- 15 Dec 2026 (estimated)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
After obtaining informed consent from the patients, all the medical history and treatment records of the patients who underwent gastroscopy since the onset of the disease, as well as gastric fluid samples, including laboratory and imaging data, were collected and recorded. The medical history and treatment records and gastric fluid samples were analyzed.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| gastric cancer | – | Diagnostic Test: In vitro surface plasmon resonance detectionPatients diagnosed with gastric cancer |
Who may qualify
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Gastric cancer and non-cancer patients
Key inclusion criteria (3 listed)
- Patients underwent gastroscopy and treatment at the Endoscopy Center of Beijing Friendship Hospital, Capital Medical University, and received pathological biopsy.
- Previous gastroscopy suggested the possibility of lesions.
- No previous history of gastrointestinal cancer.
Key exclusion criteria (5 listed)
- Patients could not cooperate with the examination or had contraindications to endoscopy.
- Previous history of gastrointestinal tumors, gastrointestinal surgery, physical and chemical injuries of the gastrointestinal tract.
- Severe bile reflux.
- Take simethicone and other defoaming agents before examination.
- Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| In vitro surface plasmon resonance detectionGastric juice from patients was removed for isolation of extracellular vesicles and surface plasmon resonance detection in vitro | Diagnostic test | gastric cancer |
Primary outcome
Surface plasmon resonance(SPR) detection of extracellular vesicles in gastric juice of patients with gastric cancer has large shift and spectral changes
Time frame: baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2026.
Related trials for Gastric Cancer (GC)
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Recruiting
TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
Gastric Cancer (GC), Stomach Neoplasms
Not yet recruitingPhase 2
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
RecruitingPhase 2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Gastroesophageal Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric Cancer (GC) and Gastric Cancer (Diagnosis), run by Beijing Friendship Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hao-Su Zhan, Dr. (13565915192, 1509082764@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Surface plasmon resonance(SPR) detection of extracellular vesicles in gastric juice of patients with gastric cancer has large shift and spectral changes (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.